US Patent

US12350267 — Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases

Method of Use · Assigned to Shire Human Genetics Therapies Inc · Expires 2032-10-26 · 6y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating pediatric cholestatic liver diseases by non-systemically administering a pediatric formulation of an Apical Sodium-dependent Bile Acid Transporter Inhibitor.

USPTO Abstract

Provided herein are methods of treating or ameliorating a pediatric cholestatic liver disease by non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an Apical Sodium-dependent Bile Acid Transporter Inhibitor (ASBTI) or a pharmaceutically acceptable salt thereof. Also provided are methods for treating or ameliorating a pediatric liver disease, decreasing the levels of serum bile acids or hepatic bile acids, treating or ameliorating pruritis, reducing liver enzymes, or reducing bilirubin comprising non-systemically administering to an individual in need thereof a therapeutically effective amount of a pediatric formulation comprising an ASBTI or a pharmaceutically acceptable salt thereof.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-3973 — maralixibat-chloride
U-3973 — maralixibat-chloride
U-3973 — maralixibat-chloride
U-3973 — maralixibat-chloride
U-3973 — maralixibat-chloride

Patent Metadata

Patent number
US12350267
Jurisdiction
US
Classification
Method of Use
Expires
2032-10-26
Drug substance claim
No
Drug product claim
No
Assignee
Shire Human Genetics Therapies Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.